- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
Pharmaceuticals - Community Register
Community register of medicinal products for human use |
AUTHORISED |
Product information |
| Invented name: | ADCETRIS
|
| Auth. number : | EU/1/12/794 |
| Active substance : | Brentuximab vedotin |
| Orphan market exclusivity for "Treatment of anaplastic large cell lymphoma" (based on designation EU/3/08/595) started on 30/10/2012 10 years of market exclusivity This orphan market exclusivity will expire on 30/10/2022 Orphan market exclusivity for "Treatment of Hodgkin lymphoma" (based on designation EU/3/08/596) started on 30/10/2012 10 years of market exclusivity This orphan market exclusivity will expire on 30/10/2022 | |
| ATC: | Anatomical main group: L - Antineoplastic and immunomodulating agents Therapeutic subgroup: L01 - Antineoplastic agents Pharmacological subgroup: L01X - Other antineoplastic agents Chemical subgroup: L01XC - Monoclonal antibodies Chemical substance: L01XC12 - Brentuximab vedotin (See WHO ATC Index) |
| Indication: | Ttreatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). |
| Marketing Authorisation Holder: | Takeda Pharma A/S
Dybendal Alle 10, 2630 Taastrup, Danmark |
|
EPAR and active package presentations | |
Package presentations | |
|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information". Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register. |
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 30/10/2012 | Centralised - Authorisation | EMEA/H/C/2455 | (2012)7764 of 25/10/2012 | |||
| 21/02/2013 | Centralised - Variation | EMEA/H/C/2455/II/2 | ||||
| Updated with Decision(2013)5596 of 26/08/2013 | ||||||
| 08/05/2013 | Centralised - Variation | EMEA/H/C/2455/IAin/4 | ||||
| Updated with Decision(2013)5596 of 26/08/2013 | ||||||
| 28/08/2013 | Centralised - Annual renewal | EMEA/H/C/2455/R/5 | (2013)5596 of 26/08/2013 | |||
| 28/10/2013 | Centralised - Transfer Marketing Authorisation Holder | EMEA/H/C/2455/T/6 | (2013)7203 of 24/10/2013 | |||
| 21/11/2013 | Centralised - Variation | EMEA/H/C/2455/II/7, 8 | ||||
| Updated with Decision(2014)6095 of 22/08/2014 | ||||||
| 23/01/2014 | Centralised - Variation | EMEA/H/C/2455/II/9, 11 | ||||
| Updated with Decision(2014)6095 of 22/08/2014 | ||||||
| 20/03/2014 | Centralised - Variation | EMEA/H/C/2455/II/10 | ||||
| Updated with Decision(2014)6095 of 22/08/2014 | ||||||
| 26/06/2014 | Centralised - Variation | EMEA/H/C/2455/II/12 | ||||
| Updated with Decision(2014)6095 of 22/08/2014 | ||||||
| 24/07/2014 | Centralised - Variation | EMEA/H/C/2455/II/18 | ||||
| Updated with Decision(2015)4708 of 03/07/2015 | ||||||
| 26/08/2014 | Centralised - Annual renewal | EMEA/H/C/2455/R/17 | (2014)6095 of 22/08/2014 | |||
| 20/11/2014 | Centralised - Variation | EMEA/H/C/2455/II/20 | ||||
| Updated with Decision(2015)4708 of 03/07/2015 | ||||||
| 02/03/2015 | Centralised - Variation | EMEA/H/C/2455/IAin/24 | ||||
| Updated with Decision(2015)4708 of 03/07/2015 | ||||||
| 07/07/2015 | Centralised - Yearly update | (2015)4708 of 03/07/2015 | ||||
| 14/09/2015 | Centralised - Annual renewal | EMEA/H/C/2455/R/26 | (2015)6315 of 10/09/2015 | |||
| 23/11/2015 | Centralised - 2-Monthly update | EMEA/H/C/2455/II/28 | (2015)8266 of 19/11/2015 | |||
| 21/12/2015 | Centralised - Variation | EMEA/H/C/2455/IAIN/29/G | ||||
| Updated with Decision(2016)4070 of 24/06/2016 | ||||||
| 15/03/2016 | Centralised - Variation | EMEA/H/C/2455/IB/34/G | ||||
| Updated with Decision(2016)4070 of 24/06/2016 | ||||||
| 01/04/2016 | Centralised - Variation | EMEA/H/C/2455/II/32 | ||||
| Updated with Decision(2016)4070 of 24/06/2016 | ||||||
| 28/04/2016 | Centralised - Variation | EMEA/H/C/2455/II/30/G | ||||
| Updated with Decision(2016)4070 of 24/06/2016 | ||||||
| 28/04/2016 | Centralised - Variation | EMEA/H/C/2455/II/33 | ||||
| Updated with Decision(2016)4070 of 24/06/2016 | ||||||
| 28/06/2016 | Centralised - Variation | EMEA/H/C/2455/IB/38 | ||||
| Updated with Decision(2016)6877 of 21/10/2016 | ||||||
| 28/06/2016 | Centralised - 2-Monthly update | EMEA/H/C/2455/II/25 | (2016)4070 of 24/06/2016 | |||
| 25/10/2016 | Centralised - Annual renewal | EMEA/H/C/2455/R/35 | (2016)6877 of 21/10/2016 | |||
| 14/11/2016 | Centralised - Variation | EMEA/H/C/2455/IAin/40 | ||||
| 14/01/2017 | Centralised - Variation | EMEA/H/C/2455/IB/44 | ||||
| 22/06/2017 | Centralised - Variation | EMEA/H/C/2455/II/45 | ||||
| 19/07/2017 | Centralised - Variation | EMEA/H/C/2455/IAIN/52 | ||||


